StockData
UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31

Unicycive Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$3.51+0.15 (+4.46%)

Close on Oct 19, 2026

Market cap
$94.48M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Oct 27, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 12, 2026Before market open–$-0.06–
Q1 FY2026
Ended Mar 31, 2026
May 12, 2026Before market open–$-0.54–
Q4 FY2025
Ended Dec 31, 2025
Mar 30, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Oct 28, 2025Before market open–––
Q2 FY2025
Ended Jun 30, 2025
Aug 14, 2025Before market open–$-0.52–
Q1 FY2025
Ended Mar 31, 2025
May 14, 2025Before market open–––
Q4 FY2024
Ended Dec 31, 2024
Mar 31, 2025After market close–––
Q3 FY2024
Ended Sep 30, 2024
Nov 13, 2024Before market open–$-0.05–
Q2 FY2024
Ended Jun 30, 2024
Aug 14, 2024Before market open–––
Q1 FY2024
Ended Mar 31, 2024
May 13, 2024After market close–––
Q4 FY2023
Ended Dec 31, 2023
Mar 29, 2024After market close–––

Press releases

Announcements Unicycive Therapeutics filed with the SEC